Outlook Therapeutics Inc. Aktie

WKN: A2PF3C / ISIN: US69012T2069

Bid: - Ask: -

Echtzeit-Preisindikation vom - um - Uhr!

- -

gettex

Zeitraum Zeitraum

Zeiteinheit

Vergleich mit Index

ISIN

Chart Style Chart Typ

Vergleichsreihen

Skalierung

Logarithmisch

Prozentual

Volumen

Volumen

Draw Chart

Indikatoren Gleitender Durchschnitt

Im Kursbereich

Technische Indikatoren

Outlook Therapeutics Inc. Chart

28.11. 01:00 - www.zacks.com OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study Outlook Therapeutics stock tanks 65% as ONS-5010 fails to meet the pre-specified non-inferiority endpoint at week 8 in the 90-day
06.11. 14:05 - www.globenewswire.com Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference Live fireside chat with CEO, Russ Trenary, on November 12th at 2:30 PM ET Live fireside chat with CEO, Russ
12.10. 03:00 - www.globenewswire.com OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights
14.08. 13:05 - www.globenewswire.com Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update ISELIN, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that has
30.07. 15:10 - www.globenewswire.com Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024 Company to participate in a fireside chat on Monday, August 5th at 8:00 AM ET
11.06. 15:05 - www.globenewswire.com Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference ISELIN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on
16.05. 20:35 - seekingalpha.com Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript
15.05. 23:00 - www.globenewswire.com Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update ISELIN, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to
13.05. 14:50 - www.globenewswire.com Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD ISELIN, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to
09.05. 14:45 - www.globenewswire.com Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast ISELIN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to